Ndeye-Aicha Gueye1,2, Timothy J Mead1, Christopher D Koch1,3, Charles V Biscotti4, Tommaso Falcone2, Suneel S Apte1. 1. Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195. 2. Department of Obstetrics and Gynecology and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio 44195. 3. Department of Chemistry, Cleveland State University, Cleveland, Ohio 44115. 4. Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio 44195.
Abstract
Context: Leiomyomas have abundant extracellular matrix (ECM), with upregulation of versican, a large proteoglycan. Objective: We investigated ADAMTS (a disintegrin-like and metalloprotease with thrombospondin type 1 motifs) protease-mediated versican cleavage in myometrium and leiomyoma and the effect of versican knockdown in leiomyoma cells. Design: We used quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blotting, immunohistochemistry, and RNA in situ hybridization for analysis of myometrium, leiomyoma and immortalized myometrium and leiomyoma cells. Short interfering RNA (siRNA) was used to knockdown versican in leiomyoma cells. Setting: This study was performed in an academic laboratory. Patients: Study subjects were women with symptomatic or asymptomatic leiomyoma. Main Outcome Measures: We quantified messenger RNAs (mRNAs) for versican splice variants. We identified ADAMTS-cleaved versican in myometrium and leiomyoma and ADAMTS messenger RNAs and examined the effect of VCAN siRNA on smooth muscle differentiation and expression of estrogen and progesterone receptors. Results: The women in the symptomatic group (n = 7) had larger leiomyoma (P = 0.01), heavy menstrual bleeding (P < 0.01), and lower hemoglobin levels (P = 0.02) compared with the asymptomatic group (n = 7), but were similar in age and menopausal status. Versican V0 and V1 isoforms were upregulated in the leiomyomas of symptomatic versus asymptomatic women (P = 0.03 and P = 0.04, respectively). Abundant cleaved versican was detected in leiomyoma and myometrium, as well as in myometrial and leiomyoma cell lines. ADAMTS4 (P = 0.03) and ADAMTS15 (P = 0.04) were upregulated in symptomatic leiomyomas. VCAN siRNA did not effect cell proliferation, apoptosis, or smooth muscle markers, but reduced ESR1 and PR-A expression (P = 0.001 and P = 0.002, respectively). Conclusions: Versican in myometrium, leiomyomas and in the corresponding immortalized cells is cleaved by ADAMTS proteases. VCAN siRNA suppresses production of estrogen receptor 1 and progesterone receptor-A. These findings have implications for leiomyoma growth.
Context:Leiomyomas have abundant extracellular matrix (ECM), with upregulation of versican, a large proteoglycan. Objective: We investigated ADAMTS (a disintegrin-like and metalloprotease with thrombospondin type 1 motifs) protease-mediated versican cleavage in myometrium and leiomyoma and the effect of versican knockdown in leiomyoma cells. Design: We used quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blotting, immunohistochemistry, and RNA in situ hybridization for analysis of myometrium, leiomyoma and immortalized myometrium and leiomyoma cells. Short interfering RNA (siRNA) was used to knockdown versican in leiomyoma cells. Setting: This study was performed in an academic laboratory. Patients: Study subjects were women with symptomatic or asymptomatic leiomyoma. Main Outcome Measures: We quantified messenger RNAs (mRNAs) for versican splice variants. We identified ADAMTS-cleaved versican in myometrium and leiomyoma and ADAMTS messenger RNAs and examined the effect of VCAN siRNA on smooth muscle differentiation and expression of estrogen and progesterone receptors. Results: The women in the symptomatic group (n = 7) had larger leiomyoma (P = 0.01), heavy menstrual bleeding (P < 0.01), and lower hemoglobin levels (P = 0.02) compared with the asymptomatic group (n = 7), but were similar in age and menopausal status. Versican V0 and V1 isoforms were upregulated in the leiomyomas of symptomatic versus asymptomatic women (P = 0.03 and P = 0.04, respectively). Abundant cleaved versican was detected in leiomyoma and myometrium, as well as in myometrial and leiomyoma cell lines. ADAMTS4 (P = 0.03) and ADAMTS15 (P = 0.04) were upregulated in symptomatic leiomyomas. VCAN siRNA did not effect cell proliferation, apoptosis, or smooth muscle markers, but reduced ESR1 and PR-A expression (P = 0.001 and P = 0.002, respectively). Conclusions: Versican in myometrium, leiomyomas and in the corresponding immortalized cells is cleaved by ADAMTS proteases. VCAN siRNA suppresses production of estrogen receptor 1 and progesterone receptor-A. These findings have implications for leiomyoma growth.
Authors: J D Sandy; J Westling; R D Kenagy; M L Iruela-Arispe; C Verscharen; J C Rodriguez-Mazaneque; D R Zimmermann; J M Lemire; J W Fischer; T N Wight; A W Clowes Journal: J Biol Chem Date: 2001-01-26 Impact factor: 5.157
Authors: Nichole M Barker; David A Carrino; Arnold I Caplan; William W Hurd; James H Liu; Huiqing Tan; Sam Mesiano Journal: Reprod Sci Date: 2015-09-29 Impact factor: 3.060
Authors: Paul A Keire; Steven L Bressler; Joan M Lemire; Badreddin Edris; Brian P Rubin; Maziar Rahmani; Bruce M McManus; Matt van de Rijn; Thomas N Wight Journal: J Biol Chem Date: 2014-10-15 Impact factor: 5.157
Authors: William Weidong Du; Burton B Yang; Tatiana A Shatseva; Bing L Yang; Zhaoqun Deng; Sze Wan Shan; Daniel Y Lee; Arun Seth; Albert J Yee Journal: PLoS One Date: 2010-11-05 Impact factor: 3.240
Authors: Daniel R McCulloch; Courtney M Nelson; Laura J Dixon; Debra L Silver; James D Wylie; Volkhard Lindner; Takako Sasaki; Marion A Cooley; W Scott Argraves; Suneel S Apte Journal: Dev Cell Date: 2009-11 Impact factor: 12.270
Authors: Sara A Carney; Hidetoshi Tahara; Carol D Swartz; John I Risinger; Hong He; Alicia B Moore; Joseph K Haseman; J Carl Barrett; Darlene Dixon Journal: Lab Invest Date: 2002-06 Impact factor: 5.662
Authors: Daniel R Martin; Salvatore Santamaria; Christopher D Koch; Josefin Ahnström; Suneel S Apte Journal: J Proteomics Date: 2021-08-25 Impact factor: 4.044
Authors: Courtney C Hong; Alan T Tang; Matthew R Detter; Jaesung P Choi; Rui Wang; Xi Yang; Andrea A Guerrero; Carl F Wittig; Nicholas Hobson; Romuald Girard; Rhonda Lightle; Thomas Moore; Robert Shenkar; Sean P Polster; Lauren M Goddard; Aileen A Ren; N Adrian Leu; Stephanie Sterling; Jisheng Yang; Li Li; Mei Chen; Patricia Mericko-Ishizuka; Lukas E Dow; Hideto Watanabe; Markus Schwaninger; Wang Min; Douglas A Marchuk; Xiangjian Zheng; Issam A Awad; Mark L Kahn Journal: J Exp Med Date: 2020-10-05 Impact factor: 14.307
Authors: Silvia Redondo-García; Carlos Peris-Torres; Rita Caracuel-Peramos; Juan Carlos Rodríguez-Manzaneque Journal: Matrix Biol Plus Date: 2020-12-30